Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO-4 open-label 58-week tavapadon safety and tolerability study in Parkinson's disease
MOH_2021-02-08_009321Phase 3Not yet recruiting
- Sponsor
- Cerevel Therapeutics
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tavapadon in Parkinson's disease (PD), sponsored by Cerevel Therapeutics. Primary endpoint: Not specified. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2021-02-08_009321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-08_009321.